Drug Trial Radar · NCT01910883
Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jul 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Sep 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first time finafloxacin was administered to humans intravenously. The principal aim of this study was to obtain safety and tolerability data when finafloxacin was administered intravenously as single and multiple doses to healthy subjects.
Conditions
- Healthy
Interventions
Finafloxacin i.v. solution 200 mgDrug
Finafloxacin i.v. solution 400 mgDrug
Finafloxacin i.v. solution 600 mgDrug
Finafloxacin i.v. solution 800 mgDrug
Finafloxacin i.v. solution 1000 mgDrug
Placebo i.v. solutionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: 1 to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit Ltd
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.